Washington, DC, United States of America

Genoveffa Franchini

This inventor holds 10 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, The United States of America as Represented by the Department of Health, New York University. Active years: 1993-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Genoveffa Franchini. Retrieved from https://idiyas.com/inventor/genoveffa-franchini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 6)

% Patents Active = 80.0

CIPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 77(Granted Patents)

Company Filing History:

4 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

3 out of 1,217

The United States of America as Represented by the Department of Health

Oregon Health & Science University

patents

5. 1 out of 255

The United States of America

patents

6. 1 out of 8,745

US Government as Represented by the Secretary of the Army

patents

7. 1 out of 34

Virogenetics Corporation

patents

where one patent can have more than one assignee

Years Active: 1993-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12162910 - Recombinant gp120 protein with V1-loop deletion (2024-12-10),

2. 10398772 - Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy (2019-09-03),

3. 7790182 - Protein vaccines against poxviruses (2010-09-07),

4. 7771729 - Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors (2010-08-10),

5. 7094408 - Immunogenicity using a combination of DNA and vaccinia virus vector vaccines (2006-08-22),

6. 6596279 - Immunodeficiency recombinant poxvirus (2003-07-22),

7. 5869313 - Molecular clones of HIV-1 viral strains MN-ST1 and BA-L, and uses thereof (1999-02-09),

8. 5576000 - Molecular clones of HIV-1 viral strains MH-ST1 and BA-L, and uses thereof (1996-11-19),

9. 5420030 - Molecular clones of HIV-1 viral strains MN-ST1 and BA-L and uses thereof (1995-05-30),

10. 5223423 - Characterization of replication competent human immunodeficiency type 2 (1993-06-29),

Title: Genoveffa Franchini: Innovator in HIV Research

Introduction

Genoveffa Franchini is a prominent inventor and researcher based in Washington, DC. She has made significant contributions to the field of HIV research, holding a total of 10 patents. Her work focuses on developing innovative solutions to combat HIV infections and improve vaccine efficacy.

Latest Patents

Franchini's latest patents include the development of recombinant gp120 proteins with a V1-loop deletion. These embodiments of recombinant HIV-1 gp120 proteins are designed to generate an immune response to HIV-1 in subjects, potentially aiding in the treatment or prevention of HIV-1 infections. Another notable patent involves compositions that combine an HIV immunogen with an agent that stimulates the Ras pathway, which is crucial for enhancing vaccine efficacy and inducing protective immune responses against HIV.

Career Highlights

Throughout her career, Franchini has worked with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services. Her research has been pivotal in advancing our understanding of HIV and developing effective therapeutic strategies.

Collaborations

Franchini has collaborated with notable figures in the field, including Robert C. Gallo and Marvin S. Reitz, Jr. These partnerships have further enriched her research and contributed to significant advancements in HIV treatment.

Conclusion

Genoveffa Franchini's innovative work in HIV research and her numerous patents highlight her dedication to improving public health. Her contributions continue to pave the way for new therapeutic approaches to combat HIV infections.

Profile summary based on public USPTO records.